Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GZR18 in Obese/Overweight Subjects
NCT06548945Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing GZR18 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 50 days, Anti-Drug Antibody at 50 days and 1 more. Started Apr 2023; status: completed.
02
Drugs
bofanglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06548945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548945.